Efgartigimod, a human IgG1 Fc fragment FcRn antagonist, has demonstrated clinically relevant increases in platelet count with associated reductions in IgG levels in a phase 3 study of patients with primary ITP following intravenous administration (ADVANCE IV).16 This evidence concerns the gene FCGRT and autoimmune thrombocytopenic purpura.